signatera | Signatera – Circulating Tumor DNA Blood Test

Keyword	CPC	PCC	Volume	Score	Length of keyword
signatera	1.65	0.4	1950	92	9

Keyword	CPC	PCC	Volume	Score
signatera	0.43	0.8	4038	5
signatera testing	1	1	5139	6
signatera portal	1.82	1	3488	87
signatera blood test	0.58	0.9	7014	78
signatera login	1.54	1	9708	22
signatera oncology portal	1.8	0.6	9982	66
signatera ctdna	0.01	0.7	5945	5
signatera mrd	0.35	0.8	1304	11
signatera test results	0.02	0.3	3977	9
signatera natera	0.25	0.2	8985	9
signatera breast cancer	1.42	0.5	6569	52
signatera colon cancer	0.52	0.1	2410	76
signatera assay	0.77	0.9	5491	52
signatera cpt code	1.26	0.7	2990	37
signatera login portal	0.03	0.9	1283	56
signatera blood test for cancer	1.67	0.9	7763	54
signatera order form	1.64	1	3109	80
signatera ctdna test	0.2	0.2	6090	94
signatera circulating tumor dna test	0.23	0.8	2178	71

Search Results related to signatera on Search Engine

Signatera – Circulating Tumor DNA Blood Test | Natera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/

WEBSignatera™ is the first tumor-specific assay for truly individualized cancer care. Personalized design for every patient. Custom-built assay—based on the unique mutation signature of each patient’s tumor—identifies and tracks tumor mutations at the source.

DA: 100 PA: 69 MOZ Rank: 61

Signatera for Patients | Natera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/patients/

WEBSignatera™ is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools. Overview. Patient Information. Clinician Information. FAQ. Is MRD testing right for you?

DA: 12 PA: 64 MOZ Rank: 11

ctDNA Testing for Colon Cancer – Signatera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/clinicians/

WEBSignatera™ is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools.

DA: 52 PA: 53 MOZ Rank: 31

Detect relapse or progression early - Mayo
mayo.edu

https://ce.mayo.edu/sites/default/files/Signatera%20Patient%20Education.pdf

WEBSignatera is a new cancer-surveillance test that is personalized for each patient. Signatera is a custom-designed test that is generated based on each patient’s unique set of tumor mutations. Knowing earlier if your cancer is likely to recur or has progressed after treatment can help you have a more informed discussion with your

DA: 98 PA: 92 MOZ Rank: 85

Natera Submits First PMA Module to the FDA for Signatera™
natera.com

https://investor.natera.com/news/news-details/2023/Natera-Submits-First-PMA-Module-to-the-FDA-for-Signatera/default.aspx

WEBOct 2, 2023 · About Signatera. Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.

DA: 88 PA: 32 MOZ Rank: 34

Cutting-edge test detects early tumor recurrence in some cancers
go.com

https://abcnews.go.com/GMA/Wellness/cutting-edge-test-detects-early-tumor-recurrence-cancers/story?id=78187359

WEBJun 10, 2021 · Signatera, a "tumor-informed" blood test developed by Natera, can detect circulating tumor DNA in the bloodstream for certain types of cancers.

DA: 55 PA: 74 MOZ Rank: 37

Testing for cancer recurrence creates a new limbo for patients
statnews.com

https://www.statnews.com/2023/10/29/ctdna-liquid-biopsy-signatera-cancer-recurrence-minimal-residual-disease/

WEBOct 29, 2023 · Signatera is a novel personalized assay designed around the patient’s tumor profile that can identify circulating tumor DNA (ctDNA) in the blood. It’s also known as a liquid biopsy. A positive...

DA: 35 PA: 60 MOZ Rank: 94

Signatera FAQ | Natera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/

WEBSignatera™ is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment, treatment response monitoring, and early recurrence monitoring. How is Signatera™ different from current biomarker tests? What can MRD testing tell me about my cancer?

DA: 82 PA: 52 MOZ Rank: 76

Signatera Test. Is it truly helpful and worthwhile?
mayoclinic.org

https://connect.mayoclinic.org/discussion/signatera-test-is-it-truly-helpful-and-worthwhile/?pg=5

WEBNov 30, 2023 · Each tumor has its own DNA signature. Natera evaluates a sample of the tumor tissue for ( about) 14 markers. The blood test then scans for fragments of those DNA markers. Each tumor is distinct. This is my understanding but you can contact Natera or go on website for information.

DA: 91 PA: 54 MOZ Rank: 11

Serial Postoperative Circulating Tumor DNA Assessment Has …
ascopubs.org

https://ascopubs.org/doi/10.1200/PO.23.00456

WEB1 day ago · PURPOSE Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and …

DA: 20 PA: 1 MOZ Rank: 20